Harwood Private Equity achieved a final exit from its investment in Celsis International Limited through a sale to a trade buyer on 24 July 2015, creating a very successful return for investors.
Celsis is a global market leader in the manufacture of diagnostic kits used to test for microbial contamination in liquid products for the pharmaceutical, personal care, dairy and beverage industries.
Harwood Private Equity acquired the company in 2009 and, as part of the business plan, divested two non-core divisions: Analytical Services, a provider of outsourced laboratory services, and In-Vitro Technologies, a global leader in the supply of cryo-preserved human liver cells in 2011 and 2013 respectively.